Categorized | Stem Cell Research

FDA Approves Continuation of Spinal Cord Repair Research


Geron can move forward with its early-stage trial of an embryonic stem cell treatment after the Food and Drug Administration lifted a clinical hold after almost a year.

The California based company first launched the study of GRNOPC1, which could potentially fix spinal cord injuries with the use of progenitor cells, that help restore nerve fibers and myelin, which is a protective sheath that protects nerves in the central nervous system. Repairing the nerves could lead to restoration of sensory function or use of extremities. The study was begun in the first quarter of last year but it was stopped seven months later after safety concerns were raised. No patients were enrolled in the study.

Related Posts with Thumbnails

Leave a Reply

Contact Us

Tips, Leads, Suggestions, Just Want to Say Hello? Email Dan or Sarah at support (at) stemcellumbilicalcordblood (dot) com